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Analyzing Pain Medication Use and Adherence in Patients with Myotonic
Dystrophy and Facioscapulohumeral Dystrophy
Abstract
Objectives: Myotonic dystrophy (DM) and facioscapulohumeral dystrophy (FSHD) are two of the most
common muscular dystrophies in adults. It has been reported that patients with these two disorders may
suffer from pain and inadequate pain management. The purpose of this study is to analyze the current
use of pain medications and develop a survey to assess pain medication use and adherence in this
patient population.
Methods: Patients registered in the National Registry for DM and FSHD at the University of Rochester
were surveyed on pain medication use and the most significant problem of their disease. After analysis of
these surveys, an additional survey was created that contained questions specifically on pain medication
use, adherence, and general questions about the patients’ pain. Questions for the survey were devised
from previous studies on medication adherence, questionnaires on medication adherence and beliefs,
and questions from the Brief Pain Inventory.
Results: In the first survey, pain medication was used by 34% of the survey respondents (n=519/1527).
Specifically, NSAIDs were used by 23.5% and opioids were used by 4% of survey respondents. In a
separate survey, pain was reported as the most burdensome problem by 8% of patients (n= 27/355). This
was greater than problems related with balance (n=10/355), fatigue (n=20/355), or gastrointestinal
distress (n=8/355).
Conclusion: Despite the low reported response that pain was the most significant problem associated
with their disease, the prevalence of pain medication use indicates that further study into the impact of
pain and pain medication use in this patient population is warranted. Specifically, investigating questions
about adherence, use, and beliefs toward pain medication will lead to an increased understanding of pain
and its treatment in this patient population. This knowledge can lead to the ability of pharmacists to
optimize pain management and to reduce adverse reactions to pain medications.
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Table 2. Pain medication, opioid, and NSAID use in FSHD and DM
(DM1 and DM2) patients

Introduction

Results

Myotonic dystrophy (DM) and facioscapulohumeral dystrophy
(FSHD) are the two most common adult muscular dystrophies.1,2 A
National Registry was created at the University of Rochester
Medical Center to connect muscular dystrophy patients and family
members with research opportunities.3

Of the 371 total responses, pain ranked as the 5th most significant
problem out of the 12 main problems reported, with 28 responses
(Table 1). In DM patients, pain was the 3rd most significant
problem, tied with mobility issues with 15 responses.

Pain is a symptom that many patients in this population have
experienced – 64% of DM patients and 82% of FSHD patients are
said to experience pain.4 Levels and locations of pain vary, although
back pain is most common.4,5 Pain can be a problematic and
debilitating symptom for patients, so it is important to understand
the impact of pain on DM and FSHD patients and how it’s managed.

Table 2 shows pain medication use in 1527 surveyed patients. Of
these patients, 34% used some sort of pain medication, 23.5% used
non-steroidal anti-inflammatory drugs (NSAIDs), and 4% used
opioids.
Table 1. Most significant problems of disease for FSHD and DM
(DM1, DM2, and DM-unknown) patients

Methods
Patients registered in the National Registry for DM and FSHD at the
University of Rochester are surveyed on medication use upon
enrollment into the Registry (n=1527). In a separate survey
(n=371), patients were asked about the most significant problem of
their disease. Data was collected anonymously over the course of
several months.
After analysis of these surveys, an additional 73-question survey
was created containing questions on basic disease and pain
information, pain medication adherence factors, beliefs on pain
medication, specific questions on opioids and NSAIDs, and pain
medication counseling. The survey was approved by SJFC IRB and
the registry’s Scientific Advisory Board and it will be electronically
sent to eligible participants in the registry in May 2015.

Muscle weakness
Mobility
Disease progression
Muscle loss
Pain
Fatigue
Balance
Cardiac
Gastrointestinal
Psychiatric
Respiratory/Speech
Genetic

FSHD
(n = 194)
94
41
28
28
13
3
3
1
1
0
2
0

DM
(n = 177)
84
15
7
7
15
17
9
9
7
6
4
3

Total
(n = 371)
178
56
35
35
28
20
12
10
8
6
6
3

Opioid use
NSAID use
Pain medication use

FSHD
(n = 575)
38
162
239

DM
(n = 952)
23
197
280

Total
(n = 1527)
61 (4.0%)
359 (23.5%)
519 (34.0%)

Conclusion
Despite pain only ranking 5th in the most significant problem
associated with their disease, it was still found to be more
significant than other commonly-reported problems including
fatigue, GI distress, and balance. The prevalence of pain medication
use indicates that further studies relating to pain and the use of
pain medications in this patient population are warranted. It can be
concluded that DM and FSHD patients use NSAIDs less than the
general population (23.5% vs. 37.5%) and use opioids more than
the general population (4% vs. 2%).6,7 Specifically, investigating
questions about adherence, use, and beliefs toward pain
medication will lead to an increased understanding of pain and its
treatment in this patient population.
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